Visfatin and global histone H3K9me levels in colon cancer

References

• World Health Organization. Cancer 2018. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer.
   Google Scholar
• Lang K, Ratke J. Leptin and adiponectin: new players in the field of tumor cell and leukocyte migration. Cell Commun Signal. 2009;7(1):10.
   PubMed Web of Science ®Google Scholar
• Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci. 2010;101(5):1286–1291.
   PubMed Web of Science ®Google Scholar
• Riondino S, Roselli M, Palmirotta R, et al. Obesity and colorectal cancer: role of adipokines in tumor initiation and progression. World J Gastroenterol. 2014;20(18):5177–5190.
   PubMed Web of Science ®Google Scholar
• Booth A, Magnuson A, Fouts J, et al. Adipose tissue, obesity and adipokines: role in cancer promotion. Horm Mol Biol Clin Investig. 2015;21(1):57–74.
   PubMed Web of Science ®Google Scholar
• Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Mapping  electoral results. Mol Cell Biol. 1994;14(2):1431–1437.
   Google Scholar
• Grolla AA, Travelli C, Genazzani AA, Sethi JK. Extracellular  nicotinamide phosphoribosyltransferase, a new cancer metabokine. Br J Pharmacol. 2016;173:2182–2194.
   PubMed Web of Science ®Google Scholar
• Carbone F, Liberale L, Bonaventura A, et al. Regulation and function of extracellular nicotinamide phosphoribosyltransferase/visfatin. Compr Physiol. 2017;7(2):603–621.
   PubMed Web of Science ®Google Scholar
• Pilz S, Mangge H, Obermayer-Pietsch B, et al. Visfatin/pre-B-cell colony-enhancing factor: a protein with various suggested functions. J Endocrinol Invest. 2007;30(2):138–144.
   PubMed Web of Science ®Google Scholar
• Luk T, Malam Z, Marshall JC. Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol. 2008;83(4):804–816.
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci. 2008;114(4):275–288.
   PubMed Web of Science ®Google Scholar
• Singh M, Benencia F. Inflammatory signals from fat: Visfatin promotes pro-inflammatory activation and leukocyte interaction in endothelial cells. The Journal of Immunology. 2017;198(1 Supplement):206.
   Web of Science ®Google Scholar
• Fatel E. C d S, Rosa FT, Simão ANC, et al. Adipokines in rheumatoid arthritis. Adv Rheumatol. 2018;58(1):25.
   PubMedGoogle Scholar
• Reddy PS, Umesh S, Thota B, et al. PBEF1/NAmPRTase/Visfatin: A potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biol Ther. 2008;7(5):663–668.
   PubMed Web of Science ®Google Scholar
• Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokine levels in gastric cancer patients: Resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol. 2009;44(7):685–690.
   PubMed Web of Science ®Google Scholar
• Fazeli MS, Dashti H, Akbarzadeh S, et al. Circulating levels of novel adipocytokines in patients with colorectal cancer. Cytokine. 2013;62(1):81–85.
   PubMed Web of Science ®Google Scholar
• Tian W, Zhu Y, Wang Y, et al. Visfatin, a potential biomarker and prognostic factor for endometrial cancer. Gynecol Oncol. 2013;129(3):505–512.
   PubMed Web of Science ®Google Scholar
• Koksal H, Ugras NS, Kurban S, Harmankaya I, Atay A, Karanis MI. Serum visfatin levels and tissue visfatin expression in patients with breast diseasesClinSurg. 2017; 2;1601.
   Google Scholar
• Revollo JR, Grimm AA, Imai SI. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 2004;279(49):50754–50763.
   PubMed Web of Science ®Google Scholar
• Kennedy BE, Sharif T, Martell E, et al. NAD + salvage pathway in cancer metabolism and therapy. Pharmacol Res. 2016;114:274–283.
   PubMed Web of Science ®Google Scholar
• Hong SM, Hwang SW, Wang T, et al. Increased nicotinamide adenine dinucleotide pool promotes colon cancer progression by suppressing reactive oxygen species level. Cancer Sci. 2019;110(2):629–638.
   PubMed Web of Science ®Google Scholar
• Yang Q, Roehrl MH, Wang JY. Proteomic profiling of antibody-inducing immunogens in tumor tissue identifies PSMA1, LAP3, ANXA3, and maspin as colon cancer markers. Oncotarget. 2018;9(3):3996–4019.
   PubMedGoogle Scholar
• Lv X, Zhang L, Zhu Y, et al. Regulative effect of Nampt on tumor progression and cell viability in human colorectal cancer. J Cancer. 2015;6(9):849–858.
   PubMed Web of Science ®Google Scholar
• Ji C, Cong R, Wang Y, et al. Relationship between NAMPT/PBEF/visfatin and prognosis of patients with malignant tumors: a systematic review and meta-analysis. Ann Transl Med. 2019;7(23):785–785.
   PubMed Web of Science ®Google Scholar
• Hufton SE, Moerkerk PT, Brandwijk R, et al. A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization. FEBS Lett. 1999;463(1–2):77–82.
   PubMed Web of Science ®Google Scholar
• Bae S-K, Kim S-R, Kim JG, et al. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Lett. 2006;580(17):4105–4113.
   PubMed Web of Science ®Google Scholar
• Neubauer K, Bednarz Misa I, Diakowska D, Kapturkiewicz B, Gamian A, Krzystek-Korpacka M. Nampt/PBEF/visfatin upregulation in colorectal tumors, mirrored in normal tissue and whole blood of colorectal cancer patients, is associated with metastasis, hypoxia, IL1β, and anemia. Biomed Res Int. 2015;2015:523930.
   Google Scholar
• Koike Folgueira MAAK, Carraro DM, Brentani H, et al. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res. 2005;11(20):7434–7443.
   PubMed Web of Science ®Google Scholar
• Yan X, Zhao J, Zhang R. Visfatin mediates doxorubicin resistance in human colorectal cancer cells via up regulation of multidrug resistance 1 (MDR1). Cancer Chemother Pharmacol. 2017;80(2):395–403.
   PubMed Web of Science ®Google Scholar
• Choudhary C, Weinert BT, Nishida Y, et al. The growing landscape of lysine acetylation links metabolism and cell signalling. Nat Rev Mol Cell Biol. 2014;15(8):536–550.
   PubMed Web of Science ®Google Scholar
• Zhang T, Kraus WL. SIRT1-dependent regulation of chromatin and transcription: Linking NAD + metabolism and signaling to the control of cellular functions. BBA. 2010;1804(8):1666–1675.
   PubMed Web of Science ®Google Scholar
• Ciccarone F, Zampieri M, Caiafa P. PARP1 orchestrates epigenetic events setting up chromatin domains. Semin Cell Dev Biol. 2017;63:123–134.
   PubMed Web of Science ®Google Scholar
• Ray SK, Li HJ, Metzger E, et al. CtBP and associated LSD1 are required for transcriptional activation by NeuroD1 in gastrointestinal endocrine cells. Mol Cell Biol. 2014;34(12):2308–2317.
   PubMed Web of Science ®Google Scholar
• Lucena-Cacace A, Otero-Albiol D, Jiménez-García MP, et al. NAMPT is a potent oncogene in colon cancer progression that modulates cancer stem cell properties and resistance to therapy through sirt1 and PARP. Clin Cancer Res. 2018;24(5):1202–1215.
   PubMed Web of Science ®Google Scholar
• Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119(7):941–953.
   PubMed Web of Science ®Google Scholar
• Hayami S, Kelly JD, Cho H-S, et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer. 2011;128(3):574–586.
   PubMed Web of Science ®Google Scholar
• Ding J, Zhang Z-M, Xia Y, et al. LSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer. Br J Cancer. 2013;109(4):994–1003.
   PubMed Web of Science ®Google Scholar